Carotuximab, also known as TRC105 or DE-122, represents a emerging antibody-drug conjugate ADC currently evaluated for combating various oncological diseases. This specific molecule selects a defined antigen, found on cancer cells, releasing a powerful cytotoxic agent directly inside the tumor area. Initial clinical studies have shown encouragement

Vadastuximab tedelpar antibody-drug compound representing a important advancement in the treatment of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a protein frequently expressed on leukemic populations. The process involves binding to CD33, leading to both cellular cytotoxicity and enhanced immune-mediated eliminati

The arrival of amivantamab presents a significant advance for individuals battling cancers exhibiting c-MET dysregulation. This innovative therapeutic, a selective agent of multiple MET kinase plus human epidermal growth factor receptor 2 (HER2), showed early efficacy in research studies, particularly in individuals whose tumors harbor detectable c